重组人粒细胞集落刺激因子在造血系统疾病中的应用

Clinical Application of Recombinant Colony-stimulating Factor(rhC-CSF)in Hematological Patients

对因急性白血病（ＡＬ）、恶性淋巴瘤、多发性骨髓瘤（ＭＭ）联合化疗及其他药物所致中性粒细胞缺乏症１９例患者予以重组人粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ）治疗，中性粒细胞绝对数（ＡＮＣ）达显效、有效分别为１３例（６８．４２％），２例（１０．５２％），总有效率７８．９４％；所需中位时间分别为８，１４天。治疗后ＡＮＣ增值１．５７～１１３６０倍，白细胞（ＷＢＣ）、ＡＮＣ达显效、有效时间明显缩短（Ｐ＜０．００５）。随着ＡＮＣ增值，患者感染、使用广谱抗生素及化疗间歇时间均缩短，对患者及时进行化疗、安全渡过化疗后骨髓抑制期，进一步杀灭体内残存肿瘤细胞及缩减整体医疗费用具有重要意义。

We reported the application of recombinant human G-CSF(rhG-CSF) in 19 patients with neutropenia caused by combined chemotheropy and other drugs used for acute leukemia,lymphoma,or multiple myeloma.The absolute neutrophilic granulocyte count(ANC)increased after treatment of rhG-CSF.The therapeutical effect was divided into two groups:markedly effective and effective.13 patients showed markedly effective and 2 patients effective.The total effective rate was 78. 94%(15/20).The medium time for neutrophilic count elevation was 8 and 14 days respectively in two groups.The values of ANC increased by 1.57～11360 times.As a result of neutrophilic elevation the time of infection and use of broad-spectrum antibiotics,and interval between chemotherapy courses decreased,which were beneficial to chemotherapy and miniaturization residual diseases.